- Category: News
- Location: Zurich
- Project date: 19 January, 2021
- Media Contact: Peter Tinschert, CEO
Respiratory Health Tech Startup Resmonics Closes its Pre-Seed Financing Round
Recently incorporated digital biomarker startup Resmonics has received financial support from the CSS Insurance in its pre-seed financing round. The due diligence was conducted by Redstone on behalf of CSS Insurance. The funding will be used to accelerate the development of its first product, a smartphone-based digital biomarker service for patients suffering from asthma or COPD, and to certify it as a medical device.
With the secured investment from CSS, Resmonics plans to enter the Swiss and European market in Q3/21. In return for its investment, CSS Insurance will take a minority stake in Resmonics. Both parties set up the deal with the goal of facilitating Resmonics' long-term growth by remaining an attractive investment opportunity for new investors in future fundraising rounds.
“We are very excited to have attracted CSS Insurance, one of the leading players in the Swiss healthcare market, as our first investor,” says Peter Tinschert, CEO and Co-Founder of Resmonics. “Their profound understanding of the evolving digital health market and strong network puts us in a unique position to grow Resmonics beyond the Swiss market.”
Peter Mittemeyer, Head of Strategy & Corporate Services, Member of the Corporate Executive Committee at CSS Insurance, points out that despite the early stage of Resmonics, CSS is confident about Resmonics’ future success: “Due to our involvement in the CSS Health Lab, we were able to follow the Resmonics’ founding team closely for a couple of years now.” He adds, “Resmonics has developed an innovative and fully scalable technology for addressing a global health challenge – the management of chronic respiratory diseases.”
Resmonics was incorporated in Zurich in October 2020 by Dr. Peter Tinschert. It develops digital biomarkers for respiratory diseases such as asthma and COPD. Its mission is to use state-of-the-art mobile sensing technology to enable patient-centric solutions that are aligned with patients’ everyday lives. Resmonics builds on the research its two founders conducted at the CSS Health Lab, a joint collaboration of ETH Zurich, University St. Gallen, and CSS Insurance.
The CSS Group insures around 1.78 million individuals and is one of Switzerland's leading health, accident and property insurers. It is the market leader in basic insurance. As a health partner, CSS provides support in making decisions regarding health and healthcare. CSS Group invests in digital health startups that contribute to a high-quality and cost-efficient healthcare system.